Panacea Biotec Limited

NSE:PANACEABIO.NS

423.8 (INR) • At close September 3, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

2026 Q12025 Q42025 Q32025 Q22025 Q12024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q1
Revenue 1,6671,325.31,634.91,473.51,157.21,364.61,5051,430.21,291.91,258.991,1521,051.21,1071,387.231,558.82,321.71,324.51,611.091,417.61,820.21,327.61,184.861,677.41,251.81,257.81,223.461,103.81,203.3992.8
Cost of Revenue 772.2520.8625.5431.9879.5969.91,140.8581.9548.6574.8477.8364.51,109.51,069.07465.91,038.8426.3588.81425.1638394.4395.55522.8368.9280.71,093.59253.4435.4244.7
Gross Profit 894.8804.51,009.41,041.6277.7394.7364.2848.3743.3684.19674.2686.7-2.5318.161,092.91,282.9898.21,022.28992.51,182.2933.2789.311,154.6882.9977.1129.87850.4767.9748.1
Gross Profit Ratio 0.5370.6070.6170.7070.240.2890.2420.5930.5750.5430.5850.653-0.0020.2290.7010.5530.6780.6350.70.6490.7030.6660.6880.7050.7770.1060.770.6380.754
Reseach & Development Expenses 000000000328.40000000390.170000000255.83000
General & Administrative Expenses 00000418.23000247.49000471.63000472.5000396.65000393.75000
Selling & Marketing Expenses 00000113.04000218.21000220.05000183.74000209.78000136.44000
SG&A 058200504.9531.27456.8508.70465.7440.40-2.5691.68000656.24000606.431,154.600530.19000
Other Expenses 990.5575.51,019.61,058.4000339.6743.30139.4686.7001,079.81,282.9898.20992.51,182.2933.2-108.430882.9977.1129.85850.4767.9748.1
Operating Expenses 990.51,157.51,019.61,058.4504.9543.2456.8848.3743.3886.57595.1686.7-2.5687.791,079.81,282.9898.2783.26992.51,182.2933.2611.521,154.6882.9977.1385.68850.4767.9748.1
Operating Income -95.7-353-10.2-16.8-227.2-148.5-92.6-128.7383.6-99.74354-137.3-323.3-369.6313.1-48.8-126.1-49.638.4266.3112.1210261.1-170.7120.2-255.81-263.9-234352.2
Operating Income Ratio -0.057-0.266-0.006-0.011-0.196-0.109-0.062-0.090.297-0.0790.307-0.131-0.292-0.2660.008-0.021-0.095-0.0310.0270.1460.0840.1770.156-0.1360.096-0.209-0.239-0.1940.355
Total Other Income Expenses Net 161.3352.65464.456.7127.376.150.9-253.3281.89-129.6370.4-188.316,452.23-504.7-481.3-446.6-476.96-438.5-454.4-439.8-802.4-439.4-534-3572,128.46174.2-751.1-663.9
Income Before Tax 65.6-0.443.847.6-170.5-21.2-16.5-77.8130.3182.15224.4233.1-511.616,082.6-491.6-530.1-572.7-526.56-400.1-188.1-327.7-592.4-178.3-704.7-236.81,872.65-89.7-985.1-311.7
Income Before Tax Ratio 0.039-00.0270.032-0.147-0.016-0.011-0.0540.1010.1450.1950.222-0.46211.593-0.315-0.228-0.432-0.327-0.282-0.103-0.247-0.5-0.106-0.563-0.1881.531-0.081-0.819-0.314
Income Tax Expense 2619.5-0.60.5-11.7-1.35.55.120.5308.930.776.149.83,707.850.400.814.870.40.93.491.523.123.528.325.9749-24.526.6
Net Income 40.5-18.945.248-158-16.63-22.8-82.9109.8-121.67193.7157-561.412,374.45-492-530.1-573.5-541.86-400.5-193.3-341.3-696.77-213.2-750-282.71,859.27-159.4-970-352.6
Net Income Ratio 0.024-0.0140.0280.033-0.137-0.012-0.015-0.0580.085-0.0970.1680.149-0.5078.92-0.316-0.228-0.433-0.336-0.283-0.106-0.257-0.588-0.127-0.599-0.2251.52-0.144-0.806-0.355
EPS 0.66-0.310.740.77-2.59-0.23-0.37-1.351.79-2.073.162.56-9.17202.03-8.03-8.65-9.36-8.85-6.54-3.16-5.58-11.38-3.48-12.25-4.6230.39-2.6-15.83-5.75
EPS Diluted 0.66-0.310.740.77-2.59-0.23-0.37-1.351.79-2.073.162.56-9.17202.02-8.03-8.65-9.36-8.85-6.54-3.16-5.58-11.38-3.48-12.25-4.6230.39-2.6-15.83-5.75
EBITDA 158.194.2143.5144.2-74.575.183.124.4235.1287.7330.7343.8-398.616,500.7135.280.516.851.78170.4400.8237.3-48.9401.4-179.1284.8-663.8255.7-556.479.2
EBITDA Ratio 0.0950.0710.0880.098-0.0640.0550.0550.0170.1820.2290.2870.327-0.3611.8950.0870.0350.0130.0320.120.220.179-0.0410.239-0.1430.226-0.5430.232-0.4620.08